Browse the evidence

GLP-1RAs may have little or no effect on pancreatic cancer risk.

Practitioners should be aware that GLP-1RAs may not significantly increase pancreatic cancer risk.

There is no clear evidence that GLP-1RAs and dual GLP-1/GIPRA enhance cardiorespiratory fitness (CRF).

Practitioners should be cautious in expecting improvements in CRF from these therapies.

Cardiovascular-Renal-Hepatic-Metabolic diseases are increasing globally, posing significant challenges for patient care and clinical research.

Healthcare providers should be aware of the increasing prevalence of these diseases.

Artificial intelligence (AI) is a pivotal tool in drug discovery for developing next-generation anti-obesity therapeutics.

Practitioners should consider integrating AI tools in their drug discovery processes for obesity treatments.

Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.

This suggests potential for new treatments targeting the Y 2 receptor in diabetes.

The long-acting PYY analogs improved glucose metabolism in diabetic db/db mice.

Indicates potential for improved glucose control in diabetic patients.

Factors affecting the feasibility of nutrition research in post-ICU patients were identified, including slow patient recruitment rates, low adherence to the intervention, and the inability to complete outcome assessments.

Understanding these feasibility challenges can help improve future nutrition intervention studies.

Differences between the groups regarding the primary outcome (composite score of physical functioning) could not be identified due to early termination.

Early termination of studies can limit the ability to draw conclusions about treatment effects.

The number of incident GLP-1 RA users in France increased from 5117 in January 2017 to 15,193 in June 2023.

Healthcare providers should be aware of the significant increase in GLP-1 RA prescriptions.

Continuation of GLP-1RAs did not appear to be associated with an increased incidence of residual gastric contents during EGD.

Practitioners can consider continuing GLP-1RAs during EGD without increased risk of residual gastric contents.

Rates of early termination of EGD were similar between groups.

Practitioners can expect similar rates of early termination of EGD regardless of GLP-1RA continuation.

There were no aspiration events in either group.

Practitioners can be reassured that there is no increased risk of aspiration events with GLP-1RA use during EGD.

There is limited evidence supporting the effectiveness of n-3-PUFA supplementation in improving or preventing loss of lean mass in both younger and older healthy adults, as well as clinical populations including oncologic patients.

Practitioners should be cautious in recommending n-3-PUFA supplementation for lean mass improvement.

Most systematic reviews concluded that n-3-PUFA supplementation did not significantly affect strength.

Strength training recommendations should not rely on n-3-PUFA supplementation.

There was no consistent impact of n-3-PUFA supplementation on functional outcome measures.

Functional improvements should not be expected from n-3-PUFA supplementation.

No statistically significant associations were identified for SGLT2 inhibitors regarding hematologic malignancy risk.

SGLT2 inhibitors may not pose a risk for hematologic malignancies, making them a safer choice in this regard.

BGM1812 was developed through a step-by-step modification process guided by structure-based drug design and molecular dynamics simulations.

Understanding the development process can inform future drug design strategies.

The study highlights a persistently elevated pulmonary aspiration risk in patients receiving semaglutide.

Anesthesiologists should be cautious of the increased aspiration risk in patients on semaglutide during surgery.

Up to 40% of adults in the United States have metabolic dysfunction-associated steatotic liver disease (MASLD).

Practitioners should be aware of the high prevalence of MASLD in adult patients.

Metabolic dysfunction-associated steatohepatitis is now a leading indication for liver transplantation.

Healthcare providers should consider MASLD as a critical factor in liver transplant evaluations.

GLP-1 receptor-based agonists and oral dipeptidyl peptidase-4 inhibitors are currently the only available treatments for metabolic diseases.

Practitioners should be aware that current treatment options are limited to GLP-1 receptor-based therapies.

Current GLP-1-based therapies face challenges such as high costs and the need for repeated administration.

Healthcare providers should consider these challenges when prescribing GLP-1 therapies.

Research is ongoing to develop improved GLP-1-based therapies, including oral small-molecule agonists and novel drug delivery strategies.

Practitioners should stay informed about emerging GLP-1 therapies that may improve patient compliance.

Tirzepatide effectively attenuated the rewarding properties of alcohol, measured through locomotor stimulation, conditioned place preference, and accumbal dopamine release.

Tirzepatide may be a potential treatment for reducing alcohol consumption and its rewarding effects.